Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema) (PEGAP001)
Effect of Macugen (Pegaptanib) on Surgical Outcomes and Growth Factors Including Vascular Endothelial Growth Factor (VEGF) Levels in Patients With Proliferative Diabetic Retinopathy (PDR) and Clinically Significant Diabetic Macular Edema (CSDME)
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Listed as NCT00446381, this NA trial focuses on Diabetic Macular Edema and Proliferative Diabetic Retinopathy and remains completed. Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Apr 2025 — Present [monthly]
Completed NA
-
Jan 2025 — Apr 2025 [monthly]
Completed NA
-
Sep 2024 — Jan 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Oct 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .